From addiction biology to empowering patients Astraea Therapeutics is a clinical-stage company developing life-changing medicines for patients fighting to overcome substance addiction to opioid painkillers, smoking, and habitual psychostimulants. Astraea’s platform technology centers around the neurobiology of relapse.   Astraea is developing oral medicines that focus on two key pathways in the brain, one genetically linked to addictive behaviors and the other shown by clinical imaging to be altered in patients struggling with addiction.